Georg-Speyer-Haus. Foto: Andreas Reeg, Tel: +40-171-5449247,,
Georg-Speyer-Haus. Foto: Andreas Reeg, Tel: +49-171-5449247,,
Georg-Speyer-Haus. Foto: Andreas Reeg, Tel: +40-171-5449247,,
Georg-Speyer-Haus. Foto: Andreas Reeg, Tel: +40-171-5449247,,
  • 2020

    Kalusche S, Vanshylla K, Kleipass F, Gruell H, Müller B, Zeng Z, Koch K, Stein S, Marcotte H, Klein F, Dietrich U.
    Lactobacilli expressing broadly neutralizing nanobodies against HIV-1 as potential vectors for HIV-1 prophylaxis?
    Vaccines 2020, V8 (4): 758.

    Dietrich U.
    Advances in Antibody-Based HIV-1 Vaccines Development.
    Vaccines 2020, 8: 44.

  • 2019

    Hemelaar J, Elangovan R, Yun J, Dickson-Tetteh L, Fleminger I, Kirtley S, Williams B, Gouws-Williams E, Ghys PD, WHO-UNAIDS Network for HIV Isolation and Characterisation*.
    Global and regional molecular epidemiology of HIV-1,1990-2015: a systematic review, global survey, and trend analysis.
    Lancet Infect Dis 2018, V19 (2): 143-155.
    The Lancet

  • 2018

    Ringel O, Vieillard V, Debré P, Eichler J, Büning H, Dietrich U.
    The hard way towards an antibody-based HIV-1 Env vaccine: lessons from other viruses.
    Viruses 2018, 10 (4): doi: 10.3390/v10040197.

    Koch B, Schult-Dietrich P, Büttner S, Dilmaghani B, Lohmann D, Baer PC, Dietrich U, Geiger H.
    Lectin affinity plasmapheresis for MERS-CoV and MARV glycoprotein clearance.
    Blood Purif 2018, 46 (2): 126-133.

    Ringel O, Müller K, Koch J, Brill B, Wolf T, Stephan C, Vieillard V, Debré P, Dietrich U.
    Optimization of the EC26-2A4 epitope in the gp41 membrane proximal external region (MPER) targeted by neutralizing antibodies from an elite controller.
    AIDS Res Hum Retrovir 2017, 34 (4): 365-374; doi: 10.1089/AID.2017.0250.

  • 2017

    Koch K, Kalusche S, Torres JL, Stanfield RL, Danquah W, Khazanehdari K, von Briesen H, Geertsma ER, Wilson IA, Wernery U, Koch-Nolte F, Ward AB, Dietrich U.
    Selection of nanobodies with broad neutralizing potential against primary HIV-1 strains using soluble subtype C gp140 envelope trimers.
    Scientific Reports 2017, 7:8390 doi: 10.1038/s41598-017-08273-7.


  • 2016

    Alam MI, Mostafa A, Kanrai P, Mueller C, Dzieciolowski J, Lenz E, Kuznetsova I, Schult-Dietrich P, Ziebuhr J, Dietrich U, Pleschka S.
    Verapamil has antiviral activities that target different steps of the influenza virus replication cycle.
    J Antivir & Antiretrovir 2016, 8 (4): 121-130.


  • 2015

    Schmier S+, Mostafa A+, Haarmann T, Bannert N, Ziebuhr J, Veljkovic V*, Dietrich U*, Pleschka S*.
    In silico prediction and experimental confirmation of amino acids in the HA conferring enhanced receptor specificity for H5N1 Influenza A viruses.
    Scientific Reports 2015, 5:11434. doi: 10.1038/srep11434. (+equal contribution; *joint last authors)

    Geiß Y, Dietrich U.
    Catch me if you can – the race between HIV and neutralizing antibodies.
    AIDS Rev 2015, 17(2): 107-113.

    Dietrich U, Landersz M, Stahl-Hennig C, Geiger C, Foley BT.
    Genetic characterization of near full length SIVdrl genomes from four captive drills (Mandrillus leucophaeus).
    AIDS Res Hum Retrovir 2015, 31(3): 353-357.

    Dietrich U.
    Elite controllers: Viruskontrolle ohne antivirale Therapie – auf Kosten des Immunsystems?
    Retroviren Bulletin 2014, 2: 2-5.
    Link to the full article

  • 2014

    Veljkovic V, Glisic S, Veljkovic N, Bojic Milinovic T, Dietrich U, Perovic VR, Colombatti A.
    Influenza vaccine as prevention for cardiovascular diseases: possible molecular mechanism.
    Vaccine 2014, 48(12): 6569-6575.

    Mori M, Nucci A, Dasso Lang MC, Humbert N, Boudier C, Debaene F, Sanglier-Cianferani S, Catala M, Schult-Dietrich P, Dietrich U, Tisné C, Mely Y, Botta M.
    Functional and structural characterization of 2-amino-4-phenylthiazole inhibitors of the HIV-1 nucleocapsid protein with antiviral activity.
    ACS Chem Biol, DOI 10.1021/cb500316h, 7.7.2014.

    Dietrich U.
    Ursprung und aktuelle Aspekte der HIV-Pandemie / Origin and current aspects of the HIV pandemic.
    Pharmakon 2014, 4: 244-249, ISSN 2195-2175; editors Hefte 4 (HIV-Therapeutika: Grundlagen und Arzneistoffe) und 5 (HIV-Therapeutika: Klinische Anwendung) 2014: Dietrich U, Holzgrabe U, Schirmeister T.

    Trott M, Weiß S, Antoni S, Koch J, von Briesen H, Hust M, Dietrich U.
    Functional characterization of two scFv-Fc antibodies from an HIV controller selected on soluble HIV-1 Env complexes: a neutralizing V3- and a trimer-specific gp41 antibody.
    PLoS ONE 2014, 9(5): e97478.

    Muik A, Stubbert LJ, Jahedi RZ, Geiß Y, Dold C, Tober R, Volk A, Klein S, Dietrich U, Yadollahi B, Falls T, Miletic H, Stojdl D, Bell JC, von Laer D. Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity and enhance oncolytic potency.

    Cancer Res 2014, 74(13): 3567-78.

    Arnold P*, Himmels P*, Weiß S*, Decker TM, Markl J, Gatterdam V, Tampé R, Bartholomäus P, Dietrich U+, Dürr R+.

    Antigenic and 3D structural characterisation of soluble X4 and hybrid X4-R5 HIV-1 Env trimers.
    Retrovirology 2014, 11:(1): 42. (*equal contribution, +joint last authors)

    Dürr R, Keppler OT, Christ F, Crespan E, Garbelli A, Maga G, Dietrich U.

    Targeting cellular cofactors in HIV therapy.
    Topics in Medicinal Chemistry DOI:10.1007/7355_2014_45, Springer-Verlag Berlin Heidelberg 2014

  • 2013

    Perovic VR, Muller CP*, Niman HL, Veljkovic N, Dietrich U, Tosic DD, Glisic S, Veljkovic V.
    Novel phylogenetic algorithm to monitor human tropism in Egyptian H5N1-HPAIV reveals evolution toward efficient human to human transmission.
    PLoS One 2013, 8(4): e61572.

    Zhou M, Meyer T, Koch S, Koch J, von Briesen H, Benito JM, Soriano V, Haberl A, Bickel M, Dübel S, Hust M, Dietrich U.
    Identification of a new epitope for HIV neutralizing antibodies in the gp41membrane proximal external region by an Env-tailored phage display library.
    Eur J Immunol, 2013, 43: 499-509.

    Dietrich U*, Dürr R, Koch J.
    Peptides as drugs: from screening to application.
    Curr Pharm Biotechnol 2013, 14: 501-512. (*corresponding author)

  • 2012

    Odaibo GN, Ola SO, Landersz M, Dietrich U, Olaleye DO.
    HIV-1 drug resistant mutations in chronically infected treatment naïve individuals in the pre-ARV era in Nigeria.
    Afr J Med Sci 2012, 41 Suppl.: 61-63.

    Mori M, Schult-Dietrich P, Szafarowicz B, Humbert N, Debaene F, Sanglier-Cianferani S, Dietrich U, Mely Y, Botta M.
    Use of virtual screening for discovering anti-retroviral compounds interacting with the HIV-1 nucleocapsid protein.
    Virus Res 2012, 169 (2): 377-87.

    Volk A, Hartmann S, Muik A, Geiß Y, Königs C, Dietrich U, von Laer D, Kimpel J. Comparison of three humanized mouse models for adoptive T cell transfer.
    J Gene Med 2012, 14(8): 540-8.

    Muik A, Dold C, Geiß Y, Volk A, Werbizki M, Dietrich U, von Laer D.
    Semi-replication-competent vesicular stomatitis virus as a novel platform for oncolytic virotherapy.
    J Mol Medicine 2012, 90(8): 959-70.

    Desimmie BA, Humbert M, Lescrinier E, Hendrix J, Vets S, Gijsbers R, Ruprecht RM, Dietrich U*, Debyser Z*, Christ F*.
    Phage Display-directed Discovery of LEDGF/p75 Binding Cyclic Peptide Inhibitors of HIV Replication.
    Molecular Therapy 2012, 20 (11): 2064-75. (*corresponding authors)

    Zhou M, Kostoula I, Brill B, Panou E, Sakarellos-Daitsiotis M, Dietrich U.
    Prime boost vaccination approaches with different conjugates of a new HIV-1 gp41 epitope encompassing the membrane proximal external region induce neutralizing antibodies in mice.
    Vaccine 2012, 30: 1911-16.

    Möbius K, Dürr R, Haußner C, Dietrich U, Eichler J.
    A functionally selective synthetic mimic of the HIV-1 coreceptor CXCR4.
    Chemistry 2012, 18(27): 8292-95.

  • 2011

    Zevgiti S, Gonzalez Zabala J, Darji A, Dietrich U, Panou-Pomonis E, Sakarellos-Daitsiotis M.
    Sialic acid and sialyl-lactose glycoconjugates: design, synthesis and binding assays to lectins and swine Influenza H1N1 virus.
    J Peptide Science 2011, 18(1): 52-58.

    Garbelli A*, Beermann S*, Di Cicco G, Dietrich U, Maga G.
    A motif unique to the human DEAD-box protein DDX3 is important for nucleic acid binding, ATP hydrolysis, RNA/DNA unwinding and HIV-1 replication.
    PLoS ONE 2011, 6(5): e19810. (*joint first authors)

    Capalbo G, Mueller-Kuller T, Markovic S, Klein SA, Dietrich U, Hoelzer D, Ottmann OG, Scheuring UJ.
    Knock-down of ERM family member moesin in host cells increases HIV-1 replication.
    AIDS Res Hum Retrovir 2011, 27(12): 1317-22.

    Funke J*, Dürr R*, Dietrich U, Koch J.
    NK cells in HIV infection: a double edged sword.
    AIDS Reviews 2011, 13(2): 67-76. (*joint first authors)

    Muik A, Kneiske I, Werbizki M, Wilfingseder D, Giroglou T, Ebert O, Kraft A, Dietrich U, Zimmer G, Momma S, von Laer D.
    Pseudotyping Vesicular Stomatitis Virus with Lymphocytic Chroriomeningitis Virus glycoproteins increases infectivity for glioma cells and reduces neurotropism.
    J Virol 2011, 85(11): 5679-84.

    Garbelli A, Radi M, Falchi F, Beermann S, Zanoli S, Dietrich U, Botta M, Maga G.
    Targeting the human DEAD-box polypeptide (DDX3) RNA helicase as a novel strategy to inhibit HIV-1 replication.
    Curr Med Chem 2011, 18(20): 3015-27.

    Liu S, Li R, Zhang R, Chan CCS, Xi B, Zhu Z, Yang J, Poon VKM, Zhou J, Chen M, Münch J, Kirchhoff F, Pleschka S, Haarmann T, Dietrich U, Pan C, Du L, Jiang S, Zheng B.
    CL-385319 inhibits H5N1 avian influenza A virus infection by blocking viral entry.
    Eur J Pharmacol 2011, 660: 460-67.

  • 2010

    Heinzelmann A, Stein S, Köhl U, Dietrich U, von Briesen H.
    Regulation of HIV-1 infection in primary CD34+ derived cells through manipulation of APOBEC3G expression.
    Curr HIV Res 2010, 8 (7): 554-63.

    Capalbo G, Müller-Kuller T, Dietrich U, Hölzer D, Ottmann OG, Scheuring UJ.
    Inhibition of HIV-1 replication by knock-down of the cellular protein LEREPO4.
    AIDS Res Hum Retrovir 2010, 26 (10): 1155-61.

    Hertje M, Zhou M, Dietrich U.
    Inhibition of HIV-1 entry: multiple keys to close the door.
    ChemMedChem 2010, 5(11): 554-63.

    Mori M, Dietrich U, Manetti F, Botta M.
    Molecular dynamics and DFT study on HIV-1 nucleocapsid protein-7 in complex with viral genome.
    J Chem Information and Modeling 2010, 50(4): 638-50.

    Capalbo G, Müller-Kuller T, Dietrich U, Hölzer D, Ottmann OG, Scheuring UJ.
    Inhibition of HIV-1 replication by small interfering RNAs directed against Glioma Pathogenesis Related Protein (GLIPR).
    Retrovirology 2010, 7: 26.

    Dieltjens T, Willems B, Coppens S, van Nieuwenhove L, Humbert M, Dietrich U, Heyndrickx L, Vanham G, Janssens W.
    Unravelling the antigenic landscape of the HIV-1 subtype A envelope of an individual with broad cross-neutralizing antibodies using phage display peptide libraries.
    J Virol Meth 2010, 169(1): 95-102.

    Dervillez X, Klaukien V, Dürr R, Koch J, Kreutz A, Haarmann T, Stoll M, Lee D, Carlomagno T, Schnierle B, Königs C, Griesinger C, Dietrich U.
    Peptide ligands targeting CD4-induced epitopes on native HIV-1 gp120 mimic CCR5 domains and inhibit HIV-1 entry.
    J Virol 2010, 84(19): 10131-10138.

  • 2009

    Kessel C, Kreuz W, Klich K, Becker-Peters K, Vorpahl F, Dietrich U, Klingebiel T, Königs C.
    Multimerization of peptide mimotopes for blocking of factor VIII neutrazing antibodies.
    ChemMedChem, 4(8): 1364-1370.

    Brandt O, Dietrich U, Koch J.
    Solid-supported peptide arrays in the investigation of protein-protein and protein-nucleic acid interactions.
    Curr Chem Biol, 3 (2): 171-179.

    Hermann FG, Egerer L, Brauer F, Dietrich U, von Laer D.
    Mutations in gp120 contribute to resistance of HIV-1 against the membrane-anchored fusion inhibitor maC46.
    J Virol, 83(10): 4844-53.

    Hermann FG, Martinius H, Egelhofer M, Giroglou T, Tonn T, Roth S, Zahn R, Schult-Dietrich P, Alexandrov A, Dietrich U, Baum C, von Laer D.
    Protein scaffold and expression level determine antiviral activity of membrane-anchored antiviral peptides.
    Hum Gene Ther, 20(4): 325-336.

    Egerer L, Hubert A, von Laer D, Dietrich U.
    The prevention of HIV infection with viral entry inhibitors
    Peptides as Drugs – Discovery and Development, Ed. Groner, Wiley-VCH.

  • 2008

    Kessel C, Königs C, Linde R, Escuriola-Ettinghausen C, Stoll H, Klingebiel T, Dietrich U, Kreuz W.
    Humoral immune responsiveness to a defined epitope on factor VIII before and after B-cell ablation with rituximab.
    Molecular Immunology, 46(1): 8-15.

    Dietz J, Koch J, Kaur A, Raja C, Stein S, Grez M, Pustowka A, Mensch S, Ferner J, Tampé R, Divita G, Mély Y, Schwalbe H, Dietrich U.
    Antiviral activity of peptide ligands for the HIV-1 packaging signal Y after binding optimization on spot synthesis peptide membranes.
    ChemMedChem, 3: 749-755.

    De Rocquiny H, Shvadchak V, Avilov S, Dong CZ, Dietrich U, Darlix JL, Mély Y.
    Targeting the viral nucleocapsid protein in anti-HIV-1 therapy.
    Mini-Rev Med Chem, 8(1) :24-35.

  • 2007

    Hüther A, Dietrich U.
    The emergence of peptides as therapeutic drugs for the inhibition of HIV-1.
    AIDS Reviews, 9: 208-17.

    Antoni S, Walz N, Landersz M, Humbert M, Seidl C, Dittmar MT, Dietrich U.
    Genetic and biological characterization of HIV-1 viruses derived from long-term non-progressors (LTNP).
    AIDS Res Hum Retrovir, 23(11): 1377-86.

    Königs C, Pustowka A, Irving J, Kessel C, Klich K, Wegner V, Rowley MJ, Mackay IR, Kreuz W, Griesinger C, Dietrich U.
    Peptide mimotopes selected with HIV-1 blocking monoclonal antibodies against CCR5 represent motifs specific for HIV-1 entry.
    Immunol Cell Biol, 85(7): 511-517.

    Humbert M, Antoni S, Brill B, Landersz M, Rodes B, Soriano V, Wintergerst U, Knechten H, Staszewski S, von Laer D, Dittmar MT, Dietrich U.
    Mimotopes selected with antibodies present in HIV-1 neutralizing sera from long-term non-progressors.
    Eur J Immunol, 37 (2): 501-515.

  • 2006

    Raja C, Ferner J, Dietrich U, Avilov S, Ficheux D, Darlix JL, de Rocquigny H, Schwalbe H, Mély Y.
    A Tryptophan-Rich peptide inhibits nucleic acid destabilization chaperoned by the HIV-1 nucleocapsid protein.
    Biochemistry, 45(30): 9254-65.

    Humbert M, Dietrich U.
    The role of neutralizing antibodies in HIV-infection.
    AIDS Reviews, 8: 51-59.

    Dervillez X, Hüther A, Schuhmacher J, Griesinger C, Cohen J, von Laer D, Dietrich U.
    Stable expression of soluble therapeutic peptides in eukaryotic cells by multimerisation: application to the HIV-1 fusion inhibitory peptide C46.
    ChemMedChem, 1: 330-339.

  • 2005

    Sticht J, Humbert M, Findlow S, Bodem J, Müller B, Dietrich U, Werner J, Kräusslich HG.
    A peptide inhibitor of HIV-1 assembly in vitro.
    Nature Struct Mol Biol, 12 (8): 671-677.

    Schreiber A, Humbert M, Benz A, Dietrich U.
    3D-Epitope Explorer (3DEX): Localization of conformational epitopes within three dimensional structures of proteins.
    J Comp Chem, 26 (9): 879-887.

    Königs C, O´Connor KH, Rowley MJ, Irving, JA, Wijeyewickrema L, Pustowka A, Dietrich U, Mackay IR.
    Requirement of multiple phage displayed peptide libraries for optimal mapping of a conformational antibody epitope on CCR5.
    J Immunol Meth, 299: 21-35.

    Pustowka A, Dietz J, Ferner J, Baumann M, Landersz M, Königs C, Schwalbe H, Dietrich U.
    Identification of peptide ligands for target RNA structures derived from the HIV-1 packaging signal psi (y) by screening phage displayed peptide libraries.
    ChemBioChem, 4: 1093-1097.